Predicting overall survival in patients (pts) with treatment-naive metastatic Merkel cell carcinoma (mMCC) treated with avelumab.

Ash Bullement,Sandra P. DAngelo,Amerah Amin,Ceilidh Stapelkamp,Anna Willis,Cameron Lilley,Anthony J. Hatswell,Murtuza Bharmal

Predicting overall survival in patients (pts) with treatment-naive metastatic Merkel cell carcinoma (mMCC) treated with avelumab.

2018

Ash Bullement
Sandra P. DAngelo
Amerah Amin
Ceilidh Stapelkamp
Anna Willis
Cameron Lilley
Anthony J. Hatswell
Murtuza Bharmal

e21620Background: Data from the JAVELIN Merkel 200 (JM 200) trial of avelumab in mMCC with a minimum follow-up of 18 mo for 88 pts who had received prior chemotherapy demonstrated robust survival e...

Keywords:

Avelumab
Merkel cell carcinoma
Pathology
Cancer research
Medicine
Chemotherapy
overall survival
Oncology
therapy naive
in patient
Internal medicine

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations